Search clinical trials for: SAR407899

Total 9 results

Sanofi

Completed

Repeated Dosing Study to Assess Safety and Tolerability in CKD-3 Patients on Stable ACE-I Treatment

Chronic Kidney Disease

Moldova, Republic of, Romania
Sanofi

Completed

A Clinical Study to Investigate the Effect of SAR425899 on Energy Expenditure in Obese Subjects

Type 2 Diabetes Mellitus

United States
Sanofi

Completed

A Study on Safety and Tolerability of SAR425899 in Overweight to Obese Subjects and Type 2 Diabetes Mellitus Patients Not Requiring Anti-Diabetic Pharmacotherapy With an Optional 6-month Safety Extension Period

Type 2 Diabetes Mellitus

United States
Sanofi

Withdrawn

Assessment of the Safety and Effect of SAR425899 Versus Placebo for the Treatment of Non-alcoholic Fatty Liver Disease (Restore)

Type 2 Diabetes Mellitus | Non-alcoholic Steatohepatitis
Sanofi

Completed

SAR407899 Single-dose in Treatment of Mild to Moderate Erectile Dysfunction (RHOKET)

Erectile Dysfunction

France
Sanofi

Completed

Multiple Ascending Dose Study in Healthy Male Subjects and Overweight to Obese Male and Female Type 2 Diabetes Mellitus (T2DM) Patients

Type 2 Diabetes Mellitus

Germany
Sanofi

Completed

A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Germany, Spain, United States, Canada, Czechia, Hungary, Mexico, Russian Federation
Sanofi

Terminated

A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI

Microvascular Coronary Artery Disease

United States, Denmark, Korea, Republic of, Netherlands, Sweden
Sanofi
Antaros Medical

Completed

A Clinical Study to Investigate if SAR425899 Binds to the Liver and Pancreas in Overweight to Obese Type 2 Diabetes Mellitus Patients

Type 2 Diabetes Mellitus

Sweden

3

Subscribe